Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis of 14 trials involving 18,558 patients indicates that while GLP-1 receptor agonists significantly improve quality of life, functional capacity, and all-cause mortality in heart failure patients (particularly those with HFpEF and obesity), they did not significantly reduce the composite of cardiovascular death and heart failure hospitalization, with mortality benefits appearing driven by cardiovascular outcomes trial subgroups rather than dedicated heart failure trials.